Log in to save to my catalogue

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell t...

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell t...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8381707

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

About this item

Full title

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Journal of neurology, 2022-02, Vol.269 (2), p.609-615

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Chimeric antigen receptor (CAR) T-cell therapy is an emerging highly effective treatment for refractory haematological malignancies. Unfortunately, its therapeutic benefit may be hampered by treatment-related toxicities, including neurotoxicity. Early aggressive treatment is paramount to prevent neurological sequelae, yet it potentially interferes...

Alternative Titles

Full title

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8381707

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8381707

Other Identifiers

ISSN

0340-5354

E-ISSN

1432-1459

DOI

10.1007/s00415-021-10766-5

How to access this item